6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Clarus IV-D | May 2017 | $880M | $790M | 3 |
| Clarus IV-A | May 2017 | $880M | $790M | 30 |
| Clarus IV-B | May 2017 | $880M | $790M | 7 |
| Clarus IV-C | May 2017 | $880M | $790M | 26 |
| Clarus DE II | September 2014 | $40M |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Emmett Cunningham | Slowing | Biotech & pharma, Medical devices | 7 | 1 |
Classified sectors of Clarus’s own portfolio companies, based on 8 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Clarus’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| ARCH Venture Partners | 1 | VBI Vaccines Inc/BC |
| Atlas Venture | 1 | AVROBIO |
| Bain Capital Life Sciences | 1 | Annexon |
| Hatteras Venture Partners |
| $40M |
| 1 |
| Clarus Defined Exit I | July 2014 | $100M | $100M | 2 |
| Clarus Lifesciences III | February 2014 | $375M | $234M | 16 |
| Clarus Ventures III GPFiled to raise in 2014, with no closing reported yet. | 2014 | $50M | $0 | 0 |
| Kurt Wheeler | Quiet | None listed | 2 | 0 |
| Nicholas Galakatos | Quiet | Biotech & pharma | 3 | 0 |
| Nicholas Simon | Quiet | None listed | 0 | 0 |
| Robert Liptak | Quiet | None listed | 0 | 0 |
| Scott Requadt | Quiet | Biotech & pharma | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| GRAYBUG VISION |
| HLM Strategic Investment | 1 | TYRX |
| HLM Venture Partners | 1 | TYRX |
| Lightstone Singapore | 1 | CATABASIS PHARMACEUTICALS |
| Lightstone Ventures | 1 | CATABASIS PHARMACEUTICALS |
| MPM BioVentures | 1 | ViewPoint Therapeutics |
| SV Life Sciences | 1 | CATABASIS PHARMACEUTICALS |
| Venbio Global Strategic | 1 | Eyconis |
| Vida Ventures | 1 | Praxis Precision Medicines |
| Virtuoso-mccarran | 1 | CATABASIS PHARMACEUTICALS |
A shared board seat: a company where filings name a Clarus partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
